SCHEMBL4223109

SCHEMBL4223109

CC(C)(C)OC(=O)N1CCCC(c2noc(-c3cscn3)n2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 4/20 0.52
HSD11B1 P28845 1/20 0.43
HPGDS O60760 1/20 0.42
TRPV3 Q8NET8 1/20 0.41
HDAC4 P56524 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
GPR119 Q8TDV5 1/20 0.39
ALOX5AP P20292 1/20 0.39
FEN1 P39748 1/20 0.39
TBK1 Q9UHD2 1/20 0.39
ALDH1A1 P00352 1/20 0.38
PRMT5 O14744 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
FPR2 P25090 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4221520 0.83 USP30 (0.58) USP30HSD11B1HPGDSTRPV3HDAC4
SCHEMBL4142458 0.83 GRM5 (0.47) HSD11B1HPGDSHDAC4HDAC6ALDH1A1
SCHEMBL4142455 0.83 GRM5 (0.47) HSD11B1HPGDSHDAC4HDAC6ALDH1A1
SCHEMBL4226723 0.83 USP30 (0.56) USP30HSD11B1HPGDSTRPV3HDAC4
SCHEMBL4226729 0.83 USP30 (0.56) USP30HSD11B1HPGDSTRPV3HDAC4
SCHEMBL4226659 0.82 HSD11B1 (0.62) USP30HSD11B1HPGDSHDAC4HDAC6
SCHEMBL4227292 0.81 USP30 (0.49) USP30HSD11B1HPGDSTRPV3HDAC4
SCHEMBL4227295 0.81 USP30 (0.49) USP30HSD11B1HPGDSTRPV3HDAC4
SCHEMBL4231271 0.80 USP30 (0.53) USP30HSD11B1TRPV3HDAC4HDAC6
SCHEMBL4223141 0.80 USP30 (0.53) USP30HSD11B1TRPV3HDAC4HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215822-A1 Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors NIKEM RESEARCH SRL (IT) 2009-08-27 US disclosed
EP-1893606-A2 SUBSTITUTED OXADIAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharma SA (CH) 2008-03-05 EP disclosed
WO-2006123255-A2 SUBSTITUTED OXADIAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215822-A1 Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors GRM5, GRM3, GRM2 USP30 1767/4885HSD11B1 3080/4885HPGDS 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.